Legacy Financial Advisors Inc. Has $837,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Legacy Financial Advisors Inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,329 shares of the biopharmaceutical company’s stock after buying an additional 684 shares during the period. Legacy Financial Advisors Inc.’s holdings in Gilead Sciences were worth $837,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Morgan Stanley raised its holdings in Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after acquiring an additional 158,794 shares during the period. Northern Trust Corp raised its holdings in Gilead Sciences by 3.5% in the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock worth $1,118,291,000 after acquiring an additional 504,475 shares during the period. Pacer Advisors Inc. raised its holdings in Gilead Sciences by 10.8% in the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock worth $408,829,000 after acquiring an additional 493,920 shares during the period. Van ECK Associates Corp raised its holdings in Gilead Sciences by 10.1% in the 4th quarter. Van ECK Associates Corp now owns 4,992,415 shares of the biopharmaceutical company’s stock worth $404,435,000 after acquiring an additional 457,576 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Gilead Sciences by 12.5% in the 3rd quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock worth $357,740,000 after acquiring an additional 531,314 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded down $0.55 during midday trading on Friday, hitting $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The stock has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company’s fifty day simple moving average is $70.55 and its two-hundred day simple moving average is $75.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.37 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. UBS Group decreased their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $83.69.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.